Most forms of glaucoma involve elevated fluid pressure in the eye that can damage the optic nerve. The John-Kenyon American Eye Institute provides regular glaucoma screenings combined with a full range of treatment options to best suit the patient, including the FDA-approved AquaFlow implant, which restores drainage to the eye and offers long-term relief for certain types of glaucoma.

Vision loss from glaucoma is permanent but can usually be prevented with early detection and treatment. The doctors at John-Kenyon employ state-of-the art instrumentation including visual field testing and optical coherence tomography (OCT3) to provide the earliest detection possible. Since there is no way to determine if glaucoma is under control based on how a person feels or from their vision, a person with glaucoma generally should be examined every three to four months for the rest of their lives.

One method of treating glaucoma is with selective laser trabeculoplasty, or SLT, a laser procedure that can help relieve pressure for some patients where other methods have not worked. SLT can help patients avoid surgery and help reduce their dependency upon pressure-relieving eye drops.

Another device that can help glaucoma patients is the Aquaflow implant. Aquaflow has been proven safe and effective in reducing the dangerously high intraocular pressure experienced by many people with glaucoma. In most cases, those who have had the AquaFlow implant and the new procedure have significantly decreased or eliminated their use of pressure-reducing medications.

The AquaFlow device is a tiny implant designed to maintain a reservoir created by your doctor or surgeon to increase fluid outflow in order to reduce pressure within the eye. The AquaFlow implantation procedure is generally low risk and has fewer postoperative complications than penetrating surgical procedures.

Talk to your doctor about the glaucoma solution that would be best for your eyes.